Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,996

Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides

Schachter, H. (1986) · Biochemistry and Cell Biology · doi:10.1139/o86-026 · Cited by 526

Biosynthetic Controls That Determine the Branching and Microheterogeneity of Protein-Bound Oligosaccharides

Schachter, H. (1986) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5209-9_2 · Cited by 510

Sequencing of N-Linked Oligosaccharides Directly from Protein Gels: In-Gel Deglycosylation Followed by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry and Normal-Phase High-Performance Liquid Chromatography

Küster, B., Wheeler, S. F., Hunter, A. P., Dwek, R. A., & Harvey, D. J. (1997) · Analytical Biochemistry · doi:10.1006/abio.1997.2199 · Cited by 358

Effect of glycosylation on antibody function: implications for genetic engineering

Wright, A. M., & Morrison, S. L. (1997) · Trends in biotechnology · doi:10.1016/s0167-7799(96)10062-7 · Cited by 317

Quantitative aspects of the matrix‐assisted laser desorption mass spectrometry of complex oligosaccharides

Harvey, D. J. (1993) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1290070712 · Cited by 265

In Pursuit of the Optimal Fed‐Batch Process for Monoclonal Antibody Production

Bibila, T. A., & Robinson, D. K. (1995) · Biotechnology Progress · doi:10.1021/bp00031a001 · Cited by 251

Overlapping distribution of two glycosyltransferases in the Golgi apparatus of HeLa cells.

Nilsson, T., Pypaert, M., Hoe, M. H., Slusarewicz, P., Berger, E. G., & Warren, W. G. (1993) · The Journal of Cell Biology · doi:10.1083/jcb.120.1.5 · Cited by 222

Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc γ receptor I and influence the synthesis of its oligosaccharide chains

Lund, J., Takahashi, N., Pound, J. D., Goodall, M. D., & Jefferis, R. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4963 · Cited by 216

Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans

Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., Wong, A., Stephan, J.-P., & Bayer, R. (2012) · mAbs · doi:10.4161/mabs.20737 · Cited by 203

Rational design and engineering of therapeutic proteins

Marshall, S. A., Lazar, G. A., Chirino, A. J., & Desjarlais, J. R. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02610-2 · Cited by 209

Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy

Wang, T. T., Maamary, J., Tan, G. S., Bournazos, S., Davis, C. W., Krammer, F., Schlesinger, S. J., Palese, P., Ahmed, R., & Ravetch, J. V. (2015) · Cell · doi:10.1016/j.cell.2015.06.026 · Cited by 198

A common glycan structure on immunoglobulin G for enhancement of effector functions

Lin, C., Tsai, M.-H., Li, S., Tsai, T.-I., Chu, K., Liu, Y.-C., Lai, M.-Y., Wu, C.-Y., Tseng, Y.-C., Shivatare, S. S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513456112 · Cited by 202

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

Bologna, L., Gotti, E., Manganini, M., Rambaldi, A., Intermesoli, T., Introna, M., & Golay, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000303 · Cited by 200

Molecular Farming of Recombinant Antibodies in Plants

Fischer, R., Liao, Y. C., Hoffmann, K. M. V., Schillberg, S., & Emans, N. (1999) · Biological Chemistry · doi:10.1515/bc.1999.102 · Cited by 197

Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities

Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6297 · Cited by 194

Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density

Niwa, R., Sakurada, M., Kobayashi, Y., Uehara, A., Matsushima, K., Ueda, R., Nakamura, K., & Shitara, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2263 · Cited by 187

Cancer immunotherapy

Schuster, M., Nechansky, A., & Kircheis, R. (2006) · Biotechnology Journal · doi:10.1002/biot.200500044 · Cited by 200

Development of a simple and rapid method for producing non‐fucosylated oligomannose containing antibodies with increased effector function

Zhou, Q., Shankara, S., Roy, A. J., Qiu, H., Estes, S. D., McVie-Wylie, A. J., Culm-Merdek, K., Park, A., Pan, C. Q., & Edmunds, T. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21598 · Cited by 189

Metabolic control of recombinant protein N‐glycan processing in NS0 and CHO cells

Baker, K. N., Rendall, M. H., Hills, A. E., Hoare, M., Freedman, R. B., & James, D. C. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1051 · Cited by 184

Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis

Holland, M., Yagi, H., Takahashi, N., Kato, K., Savage, C. O. S., Goodall, D. M., & Jefferis, R. (2005) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.11.021 · Cited by 191

Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies

Thomann, M., Reckermann, K., Reusch, D., Prasser, J., & Tejada, M. L. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.03.002 · Cited by 179

Xbp1-based engineering of secretory capacity enhances the productivity of Chinese hamster ovary cells

Tigges, M., & Fussenegger, M. (2006) · Metabolic Engineering · doi:10.1016/j.ymben.2006.01.006 · Cited by 178

Improved Virus Neutralization by Plant-produced Anti-HIV Antibodies with a Homogeneous β1,4-Galactosylated N-Glycan Profile

Strasser, R., Castilho, A., Stadlmann, J., Kunert, R., Quendler, H., Gattinger, P., Jeż, J., Rademacher, T., Altmann, F., Mach, L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014126 · Cited by 177

Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy

Binyamin, L., Alpaugh, R. K., Hughes, T. L., Lutz, C. T., Campbell, K. S., & Weiner, L. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6392 · Cited by 176

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

Satoh, M., Iida, S., & Shitara, K. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.11.1161 · Cited by 177

Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV‐1 and contains predominantly single‐GlcNAc N ‐glycans

Rademacher, T., Sack, M., Arcalís, E., Stadlmann, J., Balzer, S., Altmann, F., Quendler, H., Stiegler, G. M., Kunert, R., Fischer, R., et al. (2007) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2007.00306.x · Cited by 178

Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA

Mori, K., Kuni‐Kamochi, R., Yamane‐Ohnuki, N., Wakitani, M., Yamano, K., Imai, H., Kanda, Y., Niwa, R., Iida, S., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20326 · Cited by 174

Optimisation of the Cellular Metabolism of Glycosylation for Recombinant Proteins Produced by Mammalian Cell Systems

Butler, M. (2005) · Cytotechnology · doi:10.1007/s10616-005-4537-x · Cited by 178

A mathematical model of N-linked glycosylation

Krambeck, F. J., & Betenbaugh, M. J. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20645 · Cited by 171

Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles—Part 1: Separation-based methods

Reusch, D., Haberger, M., Maier, B., Maier, M., Kloseck, R., Zimmermann, B., Hook, M., Szabó, Z., Tep, S., Wegstein, J., et al. (2014) · mAbs · doi:10.4161/19420862.2014.986000 · Cited by 169

Towards the next generation of biomedicines by site-selective conjugation

Hu, Q., Berti, F., & Adamo, R. (2016) · Chemical Society Reviews · doi:10.1039/c4cs00388h · Cited by 167

Chemoenzymatic Synthesis and Fcγ Receptor Binding of Homogeneous Glycoforms of Antibody Fc Domain. Presence of a Bisecting Sugar Moiety Enhances the Affinity of Fc to FcγIIIa Receptor

Zou, G., Ochiai, H., Huang, W., Yang, Q., Li, C., & Wang, L. (2011) · Journal of the American Chemical Society · doi:10.1021/ja208390n · Cited by 171

Fc-Glycosylation of IgG1 is Modulated by B-cell Stimuli

Wang, J., Balog, C. I. A., Stavenhagen, K., Koeleman, C. A. M., Scherer, H. U., Selman, M. H. J., Deelder, A. M., Huizinga, T. W. J., Toes, R. E. M., & Wuhrer, M. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.004655 · Cited by 163

Glycosylation Changes on Serum Glycoproteins in Ovarian Cancer May Contribute to Disease Pathogenesis

Saldova, R., Wormald, M. R., Dwek, R. A., & Rudd, P. M. (2008) · Disease Markers · doi:10.1155/2008/601583 · Cited by 162

Engineering of glycosylation in yeast and other fungi: current state and perspectives

Pourcq, K. D., Schutter, K. D., & Callewaert, N. (2010) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-010-2721-1 · Cited by 167

High-level expression of recombinant IgG in the human cell line per.c6

Jones, D., Kroos, N., Anema, R., Van Montfort, B., Vooys, A., Kraats, S. V. D., Helm, E. V. D., Smits, S., Schouten, J., Brouwer, K., et al. (2003) · Biotechnology Progress · doi:10.1021/bp025574h · Cited by 158

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy

Almagro, J. C., Daniels‐Wells, T. R., Pérez‐Tapia, S. M., & Penichet, M. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01751 · Cited by 165

Molecular farming of recombinant antibodies in plants

Schillberg, S., Fischer, R., & Emans, N. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s000180300037 · Cited by 155

Glycosylation: impact, control and improvement during therapeutic protein production

Costa, A. R., Rodrigues, M. E., Henriques, M., Oliveira, R., & Azeredo, J. (2013) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.793649 · Cited by 159

Analysis of carbohydrates and glycoconjugates by matrix‐assisted laser desorption/ionization mass spectrometry: An update covering the period 1999–2000

Harvey, D. J. (2006) · Mass Spectrometry Reviews · doi:10.1002/mas.20080 · Cited by 156

Engineered therapeutic antibodies with improved effector functions

Kubota, T., Niwa, R., Satoh, M., Akinaga, S., Shitara, K., & Hanai, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01222.x · Cited by 156

Boosting therapeutic potency of antibodies by taming Fc domain functions

Kang, T. H., & Jung, S. T. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0345-9 · Cited by 153

Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns

del Val, I. J., Kontoravdi, C., & Nagy, J. M. (2010) · Biotechnology Progress · doi:10.1002/btpr.470 · Cited by 150

Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV

Ackerman, M. E., Das, J., Pittala, S., Broge, T. A., Linde, C., Suscovich, T. J., Brown, E. P., Bradley, T., Natarajan, H., Lin, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0161-0 · Cited by 138

N-Glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans

Castilho, A., Gattinger, P., Grass, J., Jeż, J., Pabst, M., Altmann, F., Gorfer, M., Strasser, R., & Steinkellner, H. (2011) · Glycobiology · doi:10.1093/glycob/cwr009 · Cited by 135

Changes in Antigen-specific IgG1 Fc N-glycosylation Upon Influenza and Tetanus Vaccination

Selman, M. H. J., de Jong, S. E., Soonawala, D., Kroon, F. P., Adégnika, A. A., Deelder, A. M., Hokke, C. H., Yazdanbakhsh, M., & Wuhrer, M. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014563 · Cited by 141

Glycoengineering of Antibodies for Modulating Functions

Wang, L., Tong, X., Li, C., Giddens, J. P., & Li, T. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-012911 · Cited by 140

The production of biopharmaceuticals in plant systems

Karg, S. R., & Kallio, P. T. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.07.002 · Cited by 137

Function and 3D Structure of the N-Glycans on Glycoproteins

Nagae, M., & Yamaguchi, Y. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13078398 · Cited by 134

Engineering mammalian cells in bioprocessing – current achievements and future perspectives

Lim, Y., Wong, N. S. C., Lee, Y. Y., Ku, S. C. Y., Wong, D. C. F., & Yap, M. G. S. (2010) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090363 · Cited by 138

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective

Desjarlais, J. R., Lazar, G. A., Zhukovsky, E. A., & Chu, S. Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.009 · Cited by 134

Impact of Glycosylation on Effector Functions of Therapeutic IgG

Abès, R., & Teillaud, J. (2010) · Pharmaceuticals · doi:10.3390/ph3010146 · Cited by 136

Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells

Beck, A., Bussat, M., Zorn, N., Robillard, V., Klinguer, C., Chenu, S., Goetsch, L., Corvaı̈a, N., DORSSELAER, A. V., & Haeuw, J. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.06.052 · Cited by 135

Research and development of next generation of antibody-based therapeutics

Li, J., & Zhu, Z. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.120 · Cited by 138

Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen

Tang, Y., Lou, J., Alpaugh, R. K., Robinson, M. K., Marks, J. D., & Weiner, L. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.2815 · Cited by 135

Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy

Zahavi, D. J., Aldeghaither, D. S., O’Connell, A., & Weiner, L. M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby002 · Cited by 135

A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects

Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 133

Optimization of Protein Expression in Mammalian Cells

Hunter, M., Yuan, P., Vavilala, D. T., & Fox, M. (2018) · Current Protocols in Protein Science · doi:10.1002/cpps.77 · Cited by 138

Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies

Beck, A., & Liu, H. (2019) · Antibodies · doi:10.3390/antib8010018 · Cited by 132

Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling

Li, T., Tong, X., Yang, Q., Giddens, J. P., & Wang, L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.738765 · Cited by 125

Metabolic control of recombinant monoclonal antibody N‐glycosylation in GS‐NS0 cells

Hills, A. E., Patel, A., Boyd, P., & James, D. C. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.10022 · Cited by 127

Immunotherapy of cancer

Borghaei, H., Smith, M. R., & Campbell, K. S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.067 · Cited by 137

Decreased Levels of Bisecting GlcNAc Glycoforms of IgG Are Associated with Human Longevity

Ruhaak, L. R., Uh, H., Beekman, M., Koeleman, C. A. M., Hokke, C. H., Westendorp, R. G. J., Wuhrer, M., Houwing‐Duistermaat, J. J., Slagboom, P. E., & Deelder, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012566 · Cited by 126

Analysis of N-glycans from recombinant immunoglobulin G by on-line reversed-phase high-performance liquid chromatography/mass spectrometry

Chen, X., & Flynn, G. C. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.08.012 · Cited by 127

Chronic lymphocytic leukaemia cells are efficiently killed by an anti‐CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16

de Romeuf, C., Dutertre, C., Garff‐Tavernier, M. L., Fournier, N., Gaucher, C., Glacet, A., Jorieux, S., Bihoreau, N., Behrens, C. K., Béliard, R., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06974.x · Cited by 129

Antibody Glycosylation and Inflammation

Shade, K.-T., & Anthony, R. M. (2013) · Antibodies · doi:10.3390/antib2030392 · Cited by 129

Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies

Golay, J., Andrea, A. E., & Cattaneo, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929895 · Cited by 130

Regulated Glycosylation Patterns of IgG during Alloimmune Responses against Human Platelet Antigens

Wuhrer, M., Porcelijn, L., Kapur, R., Koeleman, C. A. M., Deelder, A. M., de Haas, M., & Vidarsson, G. (2008) · Journal of Proteome Research · doi:10.1021/pr800651j · Cited by 123

Glycosylation Profile of Immunoglobulin G Is Cross-Sectionally Associated With Cardiovascular Disease Risk Score and Subclinical Atherosclerosis in Two Independent Cohorts

Menni, C., Gudelj, I., Macdonald-Dunlop, E., Mangino, M., Zierer, J., Bešić, E., Joshi, P. K., Trbojević‐Akmačić, I., Chowienczyk, P., Spector, T. D., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312174 · Cited by 119

Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans

Dekkers, G., Plomp, R., Koeleman, C. A. M., Visser, R., von Horsten, H. H., Sandig, V., Rispens, T., Wuhrer, M., & Vidarsson, G. (2016) · Scientific Reports · doi:10.1038/srep36964 · Cited by 123

Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format

Shahied, L., Tang, Y., Alpaugh, R. K., Somer, R. A., Greenspon, D., & Weiner, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407888200 · Cited by 120

Engineered vascular‐targeting antibody‐interferon‐γ fusion protein for cancer therapy

Ebbinghaus, C., Ronca, R., Kaspar, M., Grabulovski, D., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D. (2005) · International Journal of Cancer · doi:10.1002/ijc.20952 · Cited by 117

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions

Abdeldaim, D. T., & Schindowski, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102402 · Cited by 123

One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody–drug conjugates

Tang, F., Yang, Y., Tang, Y., Tang, S., Yang, L., Sun, B., Jiang, B., Dong, J., Liu, H., Huang, M., et al. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01751g · Cited by 110

Capillary electrophoresis with laser-induced fluorescence detection for detailed studies on N-linked oligosaccharide profile of therapeutic recombinant monoclonal antibodies

Kamoda, S., Ishikawa, R., & Kakehi, K. (2006) · Journal of Chromatography A · doi:10.1016/j.chroma.2006.08.028 · Cited by 115

Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid

Wuhrer, M., Selman, M. H. J., McDonnell, L. A., Kümpfel, T., Derfuss, T. J., Khademi, M., Olsson, T. P., Hohlfeld, R., Meinl, E., & Krumbholz, M. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0450-1 · Cited by 111

Chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody–drug conjugates

Tang, F., Wang, L., & Huang, W. (2017) · Nature Protocols · doi:10.1038/nprot.2017.058 · Cited by 112

Glycosylation of therapeutic proteins in different production systems

Werner, R. G., Kopp, K., & Schlueter, M. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00199.x · Cited by 113

In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure

Wright, A. M., Sato, Y., Okada, T., Chang, K. H., Endo, T., & Morrison, S. L. (2000) · Glycobiology · doi:10.1093/glycob/10.12.1347 · Cited by 111

Glycosylation and Fc Receptors

Hayes, J. M., Cosgrave, E. F. J., Struwe, W. B., Wormald, M., Davey, G. P., Jefferis, R., & Rudd, P. M. (2014) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-319-07911-0_8 · Cited by 110

Engineering therapeutic monoclonal antibodies

Liu, X., Pop, L. M., & Vitetta, E. S. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00601.x · Cited by 113

Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody

Giddens, J. P., Lomino, J. V., DiLillo, D. J., Ravetch, J. V., & Wang, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812833115 · Cited by 103

Butyrate increases production of human chimeric IgG in CHO-K1 cells whilst maintaining function and glycoform profile

Mimura, Y., Lund, J., Church, S., Dong, S., Li, J., Goodall, M. D., & Jefferis, R. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00308-2 · Cited by 103

Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system

Cacciatore, J. J., Chasin, L. A., & Leonard, E. F. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.04.003 · Cited by 106

Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase

von Horsten, H. H., Ogorek, C., Blanchard, V., Demmler, C., Giese, C., Winkler, K., Kaup, M., Berger, M., Jordan, I., & Sandig, V. (2010) · Glycobiology · doi:10.1093/glycob/cwq109 · Cited by 103

Genetic glycoengineering in mammalian cells

Narimatsu, Y., Büll, C., Chen, Y., Wandall, H. H., Yang, Z., & Clausen, H. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100448 · Cited by 103

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

Kellner, C., Otte, A., Cappuzzello, E., Klausz, K., & Peipp, M. (2017) · Transfusion Medicine and Hemotherapy · doi:10.1159/000479980 · Cited by 104

Glycoengineering of Human IgG1-Fc through Combined Yeast Expression and in Vitro Chemoenzymatic Glycosylation

Wei, Y., Li, C., Huang, W., Li, B., Strome, S. E., & Wang, L. (2008) · Biochemistry · doi:10.1021/bi800874y · Cited by 99

Sialylation as an Important Regulator of Antibody Function

Vattepu, R., Sneed, S. L., & Anthony, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818736 · Cited by 104

Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy

Jung, S. T., Kang, T. H., Kelton, W., & Georgiou, G. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.03.002 · Cited by 99

Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities

Kurogochi, M., Mori, M., Osumi, K., Tojino, M., Sugawara, S.-I., Takashima, S., Hirose, Y., Tsukimura, W., Mizuno, M., Amano, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132848 · Cited by 98

Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions

Grevys, A., Bern, M., Foss, S., Bratlie, D. B., Moen, A. R., Gunnarsen, K. S., Aase, A., Michaelsen, T. E., Sandlie, I., & Andersen, J. T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401218 · Cited by 98

Complement and cellular cytotoxicity in antibody therapy of cancer

Wang, S., & Weiner, G. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.759 · Cited by 96

Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti‐D immunoglobulin: more questions than answers

Kumpel, B. M. (2007) · Vox Sanguinis · doi:10.1111/j.1423-0410.2007.00945.x · Cited by 95

Engineering Cells for Cell Culture Bioprocessing – Physiological Fundamentals

Seth, G., Hossler, P., Yee, J. C., & Hu, W. (2006) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_017 · Cited by 99

Modulation and modeling of monoclonal antibody N‐linked glycosylation in mammalian cell perfusion reactors

Karst, D. J., Scibona, E., Serra, E., Bielser, J., Souquet, J., Stettler, M., Broly, H., Šoóš, M., Morbidelli, M., & Villiger, T. K. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26315 · Cited by 95

Antibody glycoengineering strategies in mammalian cells

Wang, Q., Chung, C., Chough, S., & Betenbaugh, M. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26567 · Cited by 95

Glycosylation control technologies for recombinant therapeutic proteins

Gupta, S. K., & Shukla, P. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9430-6 · Cited by 99

Fcγ receptors and immunomodulatory antibodies in cancer

Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 99

Ecdysteroid Receptors and their Applications in Agriculture and Medicine

Palli, S. R., Hormann, R. E., Schlattner, U., & Lezzi, M. (2005) · Vitamins and hormones · doi:10.1016/s0083-6729(05)73003-x · Cited by 92

The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo

Anthony, R. M., & Nimmerjahn, F. (2010) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e328342538f · Cited by 93

A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens

Chang, A. Y., Dao, T., Gejman, R. S., Jarvis, C. A., Scott, A., Dubrovsky, L., Mathias, M. D., Korontsvit, T., Zakhaleva, V., Curcio, M. J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92335 · Cited by 93

FcγR: The key to optimize therapeutic antibodies?

Sibéril, S., Dutertre, C., Fridman, W. H., & Teillaud, J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.12.003 · Cited by 95

N‐linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG

van Berkel, P. H. C., Gerritsen, J., Perdok, G. J., Valbjørn, J., Vink, T., van de Winkel, J. G. J., & Parren, P. W. H. I. (2009) · Biotechnology Progress · doi:10.1002/btpr.92 · Cited by 94

In vivo glyco‐engineered antibody with improved lytic potential produced by an innovative non‐mammalian expression system

Schuster, M., Jost, W. H., Mudde, G. C., Wiederkum, S., Schwager, C., Janzek, E., Altmann, F., Stadlmann, J., Stemmer, C., & Gorr, G. (2007) · Biotechnology Journal · doi:10.1002/biot.200600255 · Cited by 92

Improved Effector Functions of a Therapeutic Monoclonal Lewis Y-Specific Antibody by Glycoform Engineering

Schuster, M., Umaña, P., Ferrara, C., Brünker, P., Gerdes, C. A., Waxenecker, G., Wiederkum, S., Schwager, C., Loibner, H., Himmler, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4212 · Cited by 91

Pairing of oligosaccharides in the Fc region of immunoglobulin G

Masuda, K., Yamaguchi, Y., Kato, K., Takahashi, N., Shimada, I., & Arata, Y. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01557-x · Cited by 91

Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory FcγR functions

Sibéril, S., de Romeuf, C., Bihoreau, N., Fernandez, N., Meterreau, J.-L., Regenman, A., Nony, E., Gaucher, C., Glacet, A., Jorieux, S., et al. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.10.008 · Cited by 99

Influence of Variable N-Glycosylation on the Cytolytic Potential of Chimeric CD19 Antibodies

Barbin, K., Stieglmaier, J., Saul, D., Stieglmaier, K., Stockmeyer, B., Pfeiffer, M. M., Lang, P., & Fey, G. H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175684.28615.7b · Cited by 28

Expression of GnTIII in a recombinant anti‐CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγRIII

Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327

Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II

Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305

Improved Effector Functions of a Therapeutic Monoclonal Lewis Y-Specific Antibody by Glycoform Engineering

Schuster, M., Umaña, P., Ferrara, C., Brünker, P., Gerdes, C. A., Waxenecker, G., Wiederkum, S., Schwager, C., Loibner, H., Himmler, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4212 · Cited by 91

Engineering of protein glycosylation in Chinese hamster ovary cells

Umaña, P. (2005) · CaltechTHESIS (California Institute of Technology) · doi:10.7907/6ceh-kt92 · Cited by 1